Literature DB >> 15599479

Coronary artery bypass grafting for patients with aortoiliac occlusive disease.

Hitoshi Hirose1, Hidetaka Nakano, Atsushi Amano, Akihito Takahashi.   

Abstract

Harvest of the internal thoracic artery (ITA) in patients with aortoocclusive disease carries a risk of leg ischemia. Staged revascularization of the lower extremities and coronary artery in patients with aortoiliac occlusive disease with collateral vessels to the lower extremities via the ITA is reported. Revascularization of the aortoiliac occlusion prior to coronary artery bypass grafting can be performed in stable patients with appropriate perioperative coronary precautions. In patients with unstable angina and aortoiliac occlusion with collateral vessels to the leg via the ITA, coronary artery bypass grafting should be performed without using the ITA.

Entities:  

Mesh:

Year:  2002        PMID: 15599479     DOI: 10.1177/153857440203600406

Source DB:  PubMed          Journal:  Vasc Endovascular Surg        ISSN: 1538-5744            Impact factor:   1.089


  4 in total

1.  Multisystem revascularization.

Authors:  Zehra Jaffery; Arthur Grant
Journal:  Ochsner J       Date:  2009

2.  Deep inferior epigastric artery as a collateral pathway to the lower extremities: A case report.

Authors:  Kaoru Tada; Atsuro Murai; Yuta Nakamura; Seigo Suganuma; Hiroyuki Tsuchiya
Journal:  JPRAS Open       Date:  2022-01-23

3.  Hybrid single staged treatment of coronary arteries and aorto-iliac obstruction disease: a case report.

Authors:  Keiichiro Kasama; Yasuko Uranaka; Hiroto Tomita; Atsushi Matsumoto; Shinichi Suzuki
Journal:  J Cardiothorac Surg       Date:  2022-03-21       Impact factor: 1.637

4.  The use of both internal thoracic arteries for coronary revascularization increases the estimate of post-operative lower limb ischemia in patients with peripheral artery disease.

Authors:  Linda Renata Micali; Massimo Bonacchi; Daniel Weigel; Rosie Howe; Orlando Parise; Gianmarco Parise; Sandro Gelsomino
Journal:  J Cardiothorac Surg       Date:  2020-09-25       Impact factor: 1.637

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.